<DOC>
	<DOCNO>NCT01669226</DOCNO>
	<brief_summary>The purpose study evaluate role additional intraperitoneal chemotherapy cisplatin etoposide bulky advance epithelial ovarian cancer .</brief_summary>
	<brief_title>First-line Intraperitoneal Cisplatin Etoposide Chemotherapy Ovarian Cancer</brief_title>
	<detailed_description>This exploratory trial compare efficacy sequential chemotherapy , intraperitoneal chemotherapy follow intravenous chemotherapy , versus intravenous chemotherapy alone first-line therapy ovarian cancer .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Age ≥18 year ≤ 75 year . Epithelial ovarian cancer pathology confirm stage IIIc IV , expect lymph node metastasis alone Optimal cytoreductive surgery , include hysterectomy , bilateral salpingesoophorectomy , omentectomy , resection metastatic lesion , residual disease 1cm Available receive intraperitoneal chemotherapy 510 day postoperative , postoperative 14 day bowel resection . ECOG performance 02 . No 3 cycle chemotherapy prior surgery . Laboratory test within 7 day registration : hematopoietic : absolute neutrophil count great 1,500/mm3 ; Platelet count great 100,000/mm3 . Hepatic : bilirubin le 1.25 time upper limit normal ( ULN ) ; Bilirubin &lt; 2.0 , SGPT le 2 time ULN . Renal : creatinine le 1.6 mg/dL , OR creatinine clearance great 40 mL/min . Comply intraperitoneal chemotherapy followup . Written informed consent . Lowmalignant potential ovarian tumor . Laboratory test insufficiency . Hemoglobin &lt; 10 g/dL . Renal insufficiency serum creatinine &gt; 1.6 . Bone marrow dysfunction : absolute neutrophil count le 1,500/mm3 ; Platelet count less 80,000/mm3 . Active infection . Clinically significant gastrointestinal abnormality . Active coronary artery disease , cerebrovascular disease , restrictive obstructive pulmonary disease , congestive heart failure . Other condition could interfere provision inform consent , compliance study procedure , followup . Prior invasive malignancy within last 5 year show activity disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>intraperitoneal chemotherapy</keyword>
</DOC>